Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II CPX-351 in secondary or high-risk AML (age 60–75)
2018-004353-24Phase 2Completed
- Sponsor
- Fundación PETHEMA
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine in acute myeloid leukemia (AML), sponsored by Fundación PETHEMA. Primary endpoint: Complete remission/complete remission with incomplete hematologic recovery rate. Started Jul 2019; status: completed.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2018-004353-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004353-24.